SecBot SecBot
8-K ·Filed May 7, 2026

NUVL

Nuvalent, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001861560-26-000020
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

No revenue or guidance to trade on. The stock will move on binary PDUFA events (Sept 18 for zidesamtinib) and ASCO data presentations (May 29-June 2). Monitor for any FDA advisory committee announcements or clinical hold signals ahead of the PDUFA date.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$102.40
T+0 close · May 7, 2026 · via day close
Latest settled
−11.93%
T+20 · $90.18
Vs SPY
−15.07%
α at T+20
Next horizon
T+60
due 4mo ago
  1. T+0 · May 7 $102.40entry
  2. T+1 · 6mo ago +2.81%α +1.98% · $105.28
  3. T+5 · 6mo ago +2.75%α +1.25% · $105.22
  4. T+20 · 6mo ago −11.93%α −15.07% · $90.18
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nuvalent reported Q1 2026 results with a net loss of $109.3M ($1.39/share), wider than the $84.6M loss in Q1 2025, as R&D spending increased to $83.6M. The clinical-stage biotech reiterated key PDUFA milestones (zidesamtinib September 18, 2026) and submitted its NDA for neladalkib, but with no revenue and rising operating expenses, the quarter itself was a routine cash-burn update with no fundamental catalyst.

Key Facts

  • Net loss of $109.3M for Q1 2026, vs $84.6M in Q1 2025
  • Cash, cash equivalents and marketable securities of $1.3B as of March 31, 2026, down from $1.4B at year-end 2025
  • R&D expenses of $83.6M in Q1 2026, up from $74.4M in Q1 2025
  • G&A expenses of $35.8M in Q1 2026, up from $20.4M in Q1 2025
  • NDA for neladalkib in TKI pre-treated ALK-positive NSCLC submitted to FDA
  • Zidesamtinib NDA under FDA review with PDUFA target action date of September 18, 2026
  • Cash runway anticipated into 2029
  • Leadership promotions: Benjamin Lane to Chief Technology Operations Officer, Kirsten Duncan to VP Medical Affairs

Financial Impact

Net loss widened by $24.7M YoY to $109.3M; cash burn of ~$84.5M in Q1 2026 (from $1.37B to $1.29B)

net losscash positionR&D expensesG&A expenses

Risk Factors

  • FDA non-approval or delay for zidesamtinib (PDUFA Sept 18, 2026)
  • Neladalkib NDA could face regulatory setbacks or require additional trials
  • Cash burn rate increasing as commercial infrastructure is built pre-revenue
  • Clinical trial enrollment or data readout risks for ALKAZAR and HEROEX-1

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001861560-26-000020
Document: nuvl-20260507.htm0001861560-26-000020
Document: 0001861560-26-000020-index-headers.html0001861560-26-000020
Document: 0001861560-26-000020-index.html0001861560-26-000020
Document: 0001861560-26-000020.txt0001861560-26-000020
8-K Data (Synthetic)0001861560-26-000020

Track record

18 reports on NUVL

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +21.01% at T+60 after the Apr 7, 2026 report. 4 of 8 went positive at some point.

Filters
  1. Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
  2. Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
  3. Jul 15, 202617w ago 8-K Bullish 5/10 Entry $123.96 No price data
  4. Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
  5. Jul 6, 202619w ago Insider Cluster Neutral 3/10 Entry $123.72 No price data
  6. Jun 11, 202622w ago Insider Cluster Neutral 2/10 Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
  7. Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
  8. Jun 9, 202622w ago 8-K Bullish 8/10 Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
  9. May 7, 202627w ago 8-K Neutral 4/10 Viewing Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
  10. Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (11h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026